AVIVA STRATEGIES (FKA MGB CONSULTING)

Registrant on federal lobbying filings · filed 2025 to 2026

$896,000 Income reported

8 Clients represented

39 Filings counted

0 Former members lobbying

Income is the fees this registrant reported being paid to lobby. 1 filing on this record was restated by a later amendment and is left out of every total here. Everything on this page is grouped by the registrant's LDA id (401109532), not by name.

Clients 8

ENDEAVOR BIOMEDICINES $263,500 7 filings
ELEMENT BIOSCIENCES $239,000 7 filings
ULTRAGENYX PHARMACEUTICAL $114,000 5 filings
BEAM THERAPEUTICS $102,000 6 filings
ACT FOR ULTRA RARE $75,000 3 filings
HUNTINGTON'S DISEASE SOCIETY OF AMERICA $52,500 4 filings
TAYSHA GENE THERAPIES $30,000 4 filings
ARPA-H GO $20,000 3 filings

Reported by year 2 years

2026 $330,000 17 filings
2025 $566,000 22 filings

Issues lobbied 3

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 4

HOUSE OF REPRESENTATIVES 20
SENATE 18
Food & Drug Administration (FDA) 6
Intl Trade Administration (ITA) 3

Recent filings 40 total

Q2

ARPA-H GO

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $12,500 income · posted Jul 17, 2026

View → Q2

ACT FOR ULTRA RARE

2nd Quarter (Apr 1 - June 30) 2026 · House · $37,500 income · posted Jul 17, 2026

View → 2TY

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

2nd Quarter (Apr 1 - June 30) 2026 · $7,500 income · posted Jul 17, 2026

View → Q2Y

TAYSHA GENE THERAPIES

2nd Quarter (Apr 1 - June 30) 2026 · $20,000 income · posted Jul 17, 2026

View → 2TY

BEAM THERAPEUTICS

2nd Quarter (Apr 1 - June 30) 2026 · posted Jul 17, 2026

View → Q2

ENDEAVOR BIOMEDICINES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $51,000 income · posted Jul 17, 2026

View → Q2

ELEMENT BIOSCIENCES

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $44,000 income · posted Jul 17, 2026

View → Q1

ARPA-H GO

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $7,500 income · posted Apr 20, 2026

View → RR

ARPA-H GO

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 20, 2026

View → 1T

ULTRAGENYX PHARMACEUTICAL

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 20, 2026

View → Q1

ACT FOR ULTRA RARE

1st Quarter (Jan 1 - Mar 31) 2026 · House · $37,500 income · posted Apr 20, 2026

View → Q1Y

TAYSHA GENE THERAPIES

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 17, 2026

View → Q1Y

BEAM THERAPEUTICS

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 17, 2026

View → Q1Y

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

1st Quarter (Jan 1 - Mar 31) 2026 · $22,500 income · posted Apr 17, 2026

View → Q1

ELEMENT BIOSCIENCES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $39,000 income · posted Apr 17, 2026

View → RR

ACT FOR ULTRA RARE

1st Quarter (Jan 1 - Mar 31) 2026 · posted Apr 17, 2026

View → Q1

ENDEAVOR BIOMEDICINES

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $51,000 income · posted Apr 15, 2026

View → Q4Y

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

4th Quarter (Oct 1 - Dec 31) 2025 · $22,500 income · posted Feb 11, 2026

View → RR

HUNTINGTON'S DISEASE SOCIETY OF AMERICA

4th Quarter (Oct 1 - Dec 31) 2025 · posted Jan 15, 2026

View → Q4

BEAM THERAPEUTICS

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $51,000 income · posted Jan 15, 2026

View →

Showing the 20 most recent of 40 filings. Search the explorer for "AVIVA STRATEGIES (FKA MGB CONSULTING)".

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.